Reported Earnings • May 19
First quarter 2026 earnings released First quarter 2026 results: Revenue: NT$869.5m (up 1.9% from 1Q 2025). Net income: NT$426.7m (up 6.8% from 1Q 2025). Profit margin: 49% (up from 47% in 1Q 2025). The increase in margin was primarily driven by lower expenses. Reported Earnings • Mar 12
Full year 2025 earnings released: EPS: NT$4.51 (vs NT$4.63 in FY 2024) Full year 2025 results: EPS: NT$4.51 (down from NT$4.63 in FY 2024). Revenue: NT$1.82b (up 11% from FY 2024). Net income: NT$464.0m (down 2.6% from FY 2024). Profit margin: 26% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Declared Dividend • Mar 12
Final dividend of NT$4.30 announced Shareholders will receive a dividend of NT$4.30. Ex-date: 26th March 2026 Payment date: 16th April 2026 Dividend yield will be 5.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) nor is it covered by cash flows (264% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.6% to bring the payout ratio under control, which is less than the 33% EPS growth achieved over the last 5 years. Ankündigung • Mar 05
CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026 CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county Taiwan Reported Earnings • Nov 08
Third quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.90 loss in 3Q 2024) Third quarter 2025 results: NT$0.16 loss per share (improved from NT$0.90 loss in 3Q 2024). Revenue: NT$216.7m (up 61% from 3Q 2024). Net loss: NT$16.9m (loss narrowed 82% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. New Risk • Sep 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Cash payout ratio: 263% Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change). Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to NT$117, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 26x in the Chemicals industry in Taiwan. Total returns to shareholders of 80% over the past three years. Reported Earnings • Aug 08
Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$1.27 in 2Q 2024) Second quarter 2025 results: EPS: NT$0.37 (down from NT$1.27 in 2Q 2024). Revenue: NT$420.5m (up 4.9% from 2Q 2024). Net income: NT$37.7m (down 71% from 2Q 2024). Profit margin: 9.0% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Declared Dividend • Aug 07
Dividend of NT$0.50 announced Shareholders will receive a dividend of NT$0.50. Ex-date: 21st August 2025 Payment date: 19th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (135% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 2.5% to bring the payout ratio under control, which is less than the 28% EPS growth achieved over the last 5 years. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$95.10, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 47% over the past three years. Reported Earnings • May 07
First quarter 2025 earnings released: EPS: NT$3.89 (vs NT$4.08 in 1Q 2024) First quarter 2025 results: EPS: NT$3.89 (down from NT$4.08 in 1Q 2024). Revenue: NT$853.7m (up 3.5% from 1Q 2024). Net income: NT$399.4m (down 4.7% from 1Q 2024). Profit margin: 47% (down from 51% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Ankündigung • Apr 25
CH Biotech R&D Co., Ltd. to Report Q1, 2025 Results on May 06, 2025 CH Biotech R&D Co., Ltd. announced that they will report Q1, 2025 results on May 06, 2025 Upcoming Dividend • Mar 14
Upcoming dividend of NT$3.60 per share Eligible shareholders must have bought the stock before 20 March 2025. Payment date: 23 April 2025. Payout ratio is on the higher end at 88% but the company is not cash flow positive. Trailing yield: 4.9%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (2.7%). New Risk • Mar 05
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 96% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio). Declared Dividend • Feb 27
Dividend of NT$3.60 announced Shareholders will receive a dividend of NT$3.60. Ex-date: 20th March 2025 Payment date: 23rd April 2025 Dividend yield will be 4.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.8% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.3% to bring the payout ratio under control, which is less than the 9.9% EPS growth achieved over the last 5 years. Ankündigung • Feb 26
CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025 CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county Taiwan Ankündigung • Feb 15
CH Biotech R&D Co., Ltd. to Report Q4, 2024 Results on Feb 25, 2025 CH Biotech R&D Co., Ltd. announced that they will report Q4, 2024 results on Feb 25, 2025 Reported Earnings • Nov 07
Third quarter 2024 earnings released: NT$0.89 loss per share (vs NT$0.45 loss in 3Q 2023) Third quarter 2024 results: NT$0.89 loss per share (further deteriorated from NT$0.45 loss in 3Q 2023). Revenue: NT$134.8m (up 22% from 3Q 2023). Net loss: NT$92.0m (loss widened 111% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Oct 25
CH Biotech R&D Co., Ltd. to Report Q3, 2024 Results on Nov 05, 2024 CH Biotech R&D Co., Ltd. announced that they will report Q3, 2024 results on Nov 05, 2024 Upcoming Dividend • Aug 16
Upcoming dividend of NT$0.50 per share Eligible shareholders must have bought the stock before 23 August 2024. Payment date: 19 September 2024. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.4%). Higher than average of industry peers (2.4%). Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.96 in 2Q 2023) Second quarter 2024 results: EPS: NT$1.27 (down from NT$1.96 in 2Q 2023). Revenue: NT$400.7m (down 13% from 2Q 2023). Net income: NT$130.1m (down 32% from 2Q 2023). Profit margin: 33% (down from 41% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year. Ankündigung • Jul 30
CH Biotech R&D Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024 CH Biotech R&D Co., Ltd. announced that they will report Q2, 2024 results at 9:00 AM, Taipei Standard Time on Aug 06, 2024 Buy Or Sell Opportunity • Jul 26
Now 20% overvalued The stock has been flat over the last 90 days, currently trading at NT$82.60. The fair value is estimated to be NT$68.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 27%. Reported Earnings • May 09
First quarter 2024 earnings released: EPS: NT$4.08 (vs NT$4.05 in 1Q 2023) First quarter 2024 results: EPS: NT$4.08 (up from NT$4.05 in 1Q 2023). Revenue: NT$824.8m (up 3.0% from 1Q 2023). Net income: NT$419.1m (up 6.7% from 1Q 2023). Profit margin: 51% (up from 49% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 23% per year. Ankündigung • Apr 28
CH Biotech R&D Co., Ltd. to Report Q1, 2024 Results on May 07, 2024 CH Biotech R&D Co., Ltd. announced that they will report Q1, 2024 results on May 07, 2024 Upcoming Dividend • Mar 14
Upcoming dividend of NT$3.09 per share Eligible shareholders must have bought the stock before 21 March 2024. Payment date: 12 April 2024. Payout ratio and cash payout ratio are on the higher end at 86% and 87% respectively. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (4.8%). In line with average of industry peers (4.1%). Reported Earnings • Mar 03
Full year 2023 earnings released: EPS: NT$4.76 (vs NT$4.79 in FY 2022) Full year 2023 results: EPS: NT$4.76 (down from NT$4.79 in FY 2022). Revenue: NT$1.51b (up 5.6% from FY 2022). Net income: NT$463.3m (flat on FY 2022). Profit margin: 31% (down from 33% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Declared Dividend • Feb 29
Dividend of NT$3.09 announced Shareholders will receive a dividend of NT$3.09. Ex-date: 21st March 2024 Payment date: 12th April 2024 Dividend yield will be 4.3%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not covered by earnings (110% earnings payout ratio). However, it is well covered by cash flows (44% cash payout ratio). The dividend has increased over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 22% to bring the payout ratio under control, which is more than the 6.4% EPS growth achieved over the last 5 years. New Risk • Feb 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Dividend is not well covered by earnings (110% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to NT$82.40, the stock trades at a trailing P/E ratio of 19.7x. Average forward P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 96% over the past three years. New Risk • Dec 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to NT$94.60, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 112% over the past three years. Reported Earnings • Nov 14
Third quarter 2023 earnings released: NT$0.45 loss per share (vs NT$0.30 loss in 3Q 2022) Third quarter 2023 results: NT$0.45 loss per share (further deteriorated from NT$0.30 loss in 3Q 2022). Revenue: NT$110.9m (up 20% from 3Q 2022). Net loss: NT$43.6m (loss widened 51% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. New Risk • Oct 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (107% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Upcoming Dividend • Sep 19
Upcoming dividend of NT$1.00 per share at 2.6% yield Eligible shareholders must have bought the stock before 26 September 2023. Payment date: 18 October 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (3.7%). Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: NT$1.96 (vs NT$3.44 in 2Q 2022) Second quarter 2023 results: EPS: NT$1.96 (down from NT$3.44 in 2Q 2022). Revenue: NT$459.3m (down 34% from 2Q 2022). Net income: NT$190.0m (down 43% from 2Q 2022). Profit margin: 41% (down from 48% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Ankündigung • Aug 09
CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023 CH Biotech R&D Co., Ltd. announced its Board of Directors approved appropriations of earnings in cash dividends to shareholders of TWD 1 per share for the first half ended June 30, 2023. Total amount of cash dividends to shareholders is TWD 97,083,000. Reported Earnings • Mar 22
Full year 2022 earnings released: EPS: NT$4.79 (vs NT$3.00 in FY 2021) Full year 2022 results: EPS: NT$4.79 (up from NT$3.00 in FY 2021). Revenue: NT$1.43b (up 41% from FY 2021). Net income: NT$465.4m (up 60% from FY 2021). Profit margin: 33% (up from 29% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Mar 07
Upcoming dividend of NT$3.88 per share at 4.7% yield Eligible shareholders must have bought the stock before 14 March 2023. Payment date: 10 April 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.7%. Lower than top quartile of Taiwanese dividend payers (6.1%). Lower than average of industry peers (7.5%). Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to NT$79.00, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 14x in the Chemicals industry in Taiwan. Total returns to shareholders of 39% over the past three years. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to NT$57.30, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 12x in the Chemicals industry in Taiwan. Total loss to shareholders of 19% over the past three years. Reported Earnings • Aug 19
First half 2022 earnings released: EPS: NT$6.22 (vs NT$2.56 in 1H 2021) First half 2022 results: EPS: NT$6.22 (up from NT$2.56 in 1H 2021). Revenue: NT$1.29b (up 92% from 1H 2021). Net income: NT$603.4m (up 143% from 1H 2021). Profit margin: 47% (up from 37% in 1H 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improved over the past week After last week's 30% share price gain to NT$98.80, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in Taiwan. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 21% share price gain to NT$85.50, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 25% over the past three years. Upcoming Dividend • Mar 07
Upcoming dividend of NT$1.50 per share Eligible shareholders must have bought the stock before 14 March 2022. Payment date: 31 March 2022. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.8%). Reported Earnings • Mar 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: NT$3.45 (up from NT$1.19 in FY 2020). Revenue: NT$1.02b (up 45% from FY 2020). Net income: NT$291.5m (up 191% from FY 2020). Profit margin: 29% (up from 14% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 15% per year. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improved over the past week After last week's 16% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 26% over the past three years. Ankündigung • Feb 18
CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022 CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to NT$54.50, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 15x in the Chemicals industry in Taiwan. Total loss to shareholders of 38% over the past three years. Reported Earnings • Aug 18
First half 2021 earnings released: EPS NT$2.94 (vs NT$2.12 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: NT$671.5m (up 19% from 1H 2020). Net income: NT$248.1m (up 39% from 1H 2020). Profit margin: 37% (up from 32% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improved over the past week After last week's 27% share price gain to NT$63.00, the stock trades at a trailing P/E ratio of 53.1x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 33% over the past three years. Upcoming Dividend • Jun 16
Upcoming dividend of NT$0.50 per share Eligible shareholders must have bought the stock before 22 June 2021. Payment date: 09 July 2021. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (2.8%). Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improved over the past week After last week's 15% share price gain to NT$57.50, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 40% over the past three years. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS NT$1.19 (vs NT$2.26 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$702.2m (down 17% from FY 2019). Net income: NT$100.2m (down 47% from FY 2019). Profit margin: 14% (down from 23% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Ankündigung • Feb 24
CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021 CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021. Is New 90 Day High Low • Feb 18
New 90-day low: NT$50.00 The company is down 15% from its price of NT$58.80 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: NT$52.10 The company is down 13% from its price of NT$59.90 on 25 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period.